Sunday, July 6, 2025 7/6/2025

COG NCTN Network Group Operations Center

Award Number: U10CA180886
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/11/2014
PERIOD OF PERFORMANCE END DATE: 02/28/2026

Group Awards By:

View Award Description

COG NCTN Network Group Operations Center - PROJECT SUMMARY Since the introduction of chemotherapy for the treatment of childhood leukemia more than 60 years ago, the prognosis of childhood cancer has improved dramatically. The overall 5-year survival rate for childhood cancers, many of which were uniformly fatal in the pre-chemotherapy era, is now 84%. Progress for a number of childhood cancers, however, has been limited, with approximately 50% of children with acute myelogenous leukemia, 50% of children with high-risk neuroblastoma, and more than 90% of children with brainstem glioma, still succumbing to their disease. In the US, cancer remains the leading cause of death from disease in children greater than one year of age. Moreover, the late effects of cancer treatment, including permanent organ and tissue damage, hormonal and reproductive dysfunction and second cancers, are of special concern, with more than 40% of the estimated 360,000 survivors of childhood cancer experiencing a significant health related quality of life complication from childhood cancer and its treatment. Thus, despite our advances, development of new therapeutic approaches must be a priority for childhood cancer basic, translational and clinical researchers. The Children's Oncology Group (COG), the world's largest organization devoted exclusively to childhood and adolescent cancer research, was founded 17 years ago. The COG's multidisciplinary research team, comprised of more than 9,000 members, conducts research at more than 220 leading children's hospitals, universities, and cancer centers. This proposal is for COG, as part of the National Cancer Institute's (NCI) National Clinical Trials Network (NCTN), to continue its collaborative research work that supports the mission of improving the outcome for all children with cancer. The COG will design and conduct clinical-translational studies for children with cancer that builds on an increasing understanding of the molecular basis for pediatric malignancies and has the highest potential to improve the outcome. Using innovative clinical trial designs suitable for the study of rare diseases, we will study novel therapeutic approaches including but not limited to targeted small molecule drugs, immunotherapies and cellular therapies. The COG research portfolio importantly also includes clinical trials focused on improving the quality of life children with cancer and survivors. As more than 90% of children diagnosed with cancer in the US are treated at COG member institutions, the COG has the ability to offer a diverse population of children with cancer and their families the opportunity to participate in innovative research. This research effort includes allowing for collection and annotation of biospecimens from all children with cancer, providing the foundation for discovery and accelerating the most promising research efforts conducted in laboratories around the world. The proposal is for support of the COG Network Operations Center, clinician- scientists who develop and conduct research, and for member sites to participate through enrollment of eligible subjects.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	000	11	2/14/2025	NON-COMPETING CONTINUATION	$0
2025	2024	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	001	11	3/5/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $27,392,592 )
2024	2024	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	000	11	2/21/2024	NON-COMPETING CONTINUATION	$16,174,061
2024	2024	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	001	11	3/4/2024	NON-COMPETING CONTINUATION	$1,304,878
2024	2024	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	005	11	9/4/2024	NON-COMPETING CONTINUATION	$441,714
2024	2024	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	002	11	3/7/2024	NON-COMPETING CONTINUATION	$0
2024	2024	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	009	11	9/23/2024	NON-COMPETING CONTINUATION	$1,297,713
2024	2024	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	003	11	5/1/2024	NON-COMPETING CONTINUATION	$1,353,863
2024	2024	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	007	11	9/16/2024	NON-COMPETING CONTINUATION	$3,223,011
2024	2024	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	008	11	9/17/2024	SUPPLEMENT FOR EXPANSION	$1,900,274
2024	2024	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	006	11	9/16/2024	NON-COMPETING CONTINUATION	$69,487
2024	2024	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	004	11	5/23/2024	SUPPLEMENT FOR EXPANSION	$1,627,591
														Subtotal = $27,392,592

Issue Date FY: 2023 ( Subtotal = $26,479,393 )
2023	2023	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	013	10	7/27/2023	SUPPLEMENT FOR EXPANSION	$0
2023	2023	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	017	10	9/21/2023	SUPPLEMENT FOR EXPANSION	$3,541,929
2023	2023	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	015	10	8/31/2023	SUPPLEMENT FOR EXPANSION	$1,619,532
2023	2023	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	011	10	4/13/2023	SUPPLEMENT FOR EXPANSION	$38,908
2023	2023	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	014	10	7/28/2023	NON-COMPETING CONTINUATION	$0
2023	2023	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	012	10	7/26/2023	SUPPLEMENT FOR EXPANSION	$0
2023	2023	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	010	10	4/12/2023	SUPPLEMENT FOR EXPANSION	$2,432,383
2023	2023	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	008	10	3/16/2023	NON-COMPETING CONTINUATION	$0
2023	2023	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	007	10	3/8/2023	NON-COMPETING CONTINUATION	$15,368,398
2023	2023	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	003	9	1/12/2023	SUPPLEMENT FOR EXPANSION	$314,025
2023	2023	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	016	10	9/18/2023	SUPPLEMENT FOR EXPANSION	$3,243,049
2023	2022	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	001	9	12/9/2022	SUPPLEMENT FOR EXPANSION	$0
2023	2022	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	005	9	1/19/2023	NON-COMPETING CONTINUATION	$0
2023	2022	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	002	9	12/16/2022	SUPPLEMENT FOR EXPANSION	$0
2023	2022	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	000	9	12/8/2022	SUPPLEMENT FOR EXPANSION	$0
2023	2021	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	004	8	1/13/2023	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
2023	2021	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	006	8	1/20/2023	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
2023	2018	CHILDREN'S HOSPITAL OF PHILADELPHIA, THE	3401 CIVIC CENTER BLVD	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Treatment Research	009	5	3/17/2023	NON-COMPETING CONTINUATION	-$78,831
														Subtotal = $26,479,393

Issue Date FY: 2022 ( Subtotal = $25,569,860 )
2022	2022	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	007	9	8/24/2022	NON-COMPETING CONTINUATION	$6,020,451
2022	2022	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 290	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	002	9	3/17/2022	NON-COMPETING CONTINUATION	$1,077,793
2022	2022	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 290	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	003	9	4/28/2022	NON-COMPETING CONTINUATION	$0
2022	2022	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 290	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	005	9	5/16/2022	SUPPLEMENT FOR EXPANSION	$2,236,855
2022	2022	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 290	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	004	9	5/12/2022	NON-COMPETING CONTINUATION	$0
2022	2022	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	008	9	8/25/2022	SUPPLEMENT FOR EXPANSION	$231,296
2022	2022	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 290	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	006	9	5/24/2022	SUPPLEMENT FOR EXPANSION	$61,260
2022	2022	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	011	9	9/26/2022	NON-COMPETING CONTINUATION	$714,964
2022	2022	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	010	9	9/22/2022	SUPPLEMENT FOR EXPANSION	$0
2022	2022	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 290	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	001	9	3/8/2022	NON-COMPETING CONTINUATION	$14,889,183
2022	2022	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	009	9	9/7/2022	SUPPLEMENT FOR EXPANSION	$338,058
2022	2021	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 290	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	000	8	1/7/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
														Subtotal = $25,569,860

Issue Date FY: 2021 ( Subtotal = $38,783,281 ) (Continued on the next page)
2021	2021	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 290	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	013	8	9/14/2021	SUPPLEMENT FOR EXPANSION	$13,525,196
2021	2021	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 290	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	014	8	9/24/2021	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$615,585
2021	2021	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 1050	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	003	8	5/4/2021	SUPPLEMENT FOR EXPANSION	$3,457,853
Grand Total All Awards = $310,774,940

Page 1 of 3 (118 items)12 3

Top

All Categories

About

Search

Reports

Data Submission

Award Information

COG NCTN Network Group Operations Center

Award Number: U10CA180886

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/11/2014

PERIOD OF PERFORMANCE END DATE: 02/28/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer